Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis

This is an interventional treatment trial for Chronic Sinusitis focused on measuring randomized clinical trial, chronic rhinosinusitis, herbal extract BNO 1016, exacerbation, pharmacoeconomic, quality of life Read More

Inclusion Criteria:

• Signed informed consent including data protection declaration
• Male and female outpatients aged ≥18 and ≤75 years

• Diagnosis of bilateral chronic rhinosinusitis without nasal polyps confirmed by:

  • nasal endoscopy during the screening period (nasal endoscopy results not older than 2 month will be accepted) to confirm inflammation, mucopurulent discharge and/or oedema/mucosal obstruction primarily in middle meatus without nasal polyps being present
  • at the discretion of the investigator a historic CT (before screening and not older than 24 months) will be considered additionally for confirmation of bilateral involvement of middle meatus and paranasal sinuses without resolution of symptoms (mucosal changes within the ostiomeatal complex and/or sinuses)

• Bilateral chronic rhinosinusitis characterized by (V1 and V2):

  • presence of chronic rhinosinusitis symptoms for at least 12 weeks without complete resolution of symptoms prior to enrolment (V1)
  • a MSS ≥6 points and ≤12 points for each of the screening days observed by diary entries (MSSPAT)and on the days of Visit 1 and 2 (MSSINV)
  • on 5 random days of the screening period (or at least at days -5 to -1) assessed by MSSPAT and on the day of Visit 1 and 2 assessed by MSSINV: rhinorrhoea (anterior or posterior) and pain (facial pain or headache) of at least moderate intensity (score ≥2).

Exclusion Criteria:

• Sinus surgery within the last 2 years (solitary sinus puncture is allowed)
• Nasal concha surgery within the last 3 months
• Presence or history of uni- or bilateral nasal polyps
• Presence of moderate to severe co-morbid asthma, including allergic asthma
• Patients with mild asthma having exacerbations within 30 days prior to trial inclusion
• Patients with cystic fibrosis
• Patients with a positive skin prick test at V1 against allergens to which the patient might be exposed to during the expected individual trial duration, if clinically relevant (results not older than 12 months will be accepted)
• Clinically relevant perennial (e.g. patients with actual clinical symptoms of allergic rhinitis against house dust/-mite antigen) or actual seasonal allergic rhinitis
• Rhinitis medicamentosa (drug induced rhinitis)
• Aspirin-Exacerbated Respiratory Disease [AERD] (Aspirin sensitivity)
• Dentogenic sinusitis or otherwise unilateral sinusitis
• Presence of anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation / airflow
• Known hypersensitivity to trial medication or excipients
• Patients with rare hereditary problems of fructose intolerance, galactose intolerance, lactase deficiency or glucose-galactose malabsorption or sucrase-isomaltase insufficiency
• Signs or symptoms of acute bacterial sinusitis (e.g. fever > 38.5°C, orbital complications,severe unilateral frontal headache or toothache)
• Treatment with systemic or nasal antibiotics or corticosteroids within the last 4 weeks prior to V1
• Treatment with decongestant preparations (α-sympathomimetics), analgesics (including systemic Non-Steroidal Inflammatory Drugs [NSAIDs], except paracetamol), mucolytics / secretolytics, antihistamines, or alternative medicine preparations for treatment of common cold like symptoms or with immunomodulating properties within the last 7 days prior to V1
• Patients with gastric or duodenal ulcer
• Other diseases within 5 years prior to V1, which in the opinion of the investigator disqualifies the patient for trial enrolment (e.g. liver or kidney disease, severe somatopathic, neurological and /or psychiatric diseases, history of malignancy or alcohol or drug abuse or immunodeficiency).